An understudied type of breast cancer poses a lurking threatAn understudied type of breast cancer poses a lurking threat
University of Colorado Cancer Center member Matthew Sikora, Ph.D., is a national leader in research into an understudied subtype of breast cancer that’s on the rise in American women, is often more difficult to detect than other forms of breast cancer, and has sharply lower survival rates several years after diagnosis than the most common type of breast cancer.
A Potential Aid to Identify Women With Breast Cancer Treatment-Related Heart RisksA Potential Aid to Identify Women With Breast Cancer Treatment-Related Heart Risks
(MedPage Today) — A risk model based on readily available clinical and demographic information accurately identified women at risk of heart failure (HF) or cardiomyopathy (CM) after breast cancer treatment, a large cohort study showed.
Application…
Beauty Mogul Laura Geller Opens Up on Breast Cancer JourneyBeauty Mogul Laura Geller Opens Up on Breast Cancer Journey
Makeup mogul Laura Geller sits down with TODAY’s Jill Martin to share her journey of building her namesake brand, surviving breast cancer, and why her beauty line dedicates its marketing and message to women over 40.
Potential antibody therapy restricts the growth of aggressive and treatment-resistant breast cancersPotential antibody therapy restricts the growth of aggressive and treatment-resistant breast cancers
A new potential antibody therapy strategy which restricts the growth of treatment-resistant breast cancers has been developed by scientists.
GLP-1s and Heart Attacks, Strokes; Measles Outbreak Spreads; Using AI to Find PCPsGLP-1s and Heart Attacks, Strokes; Measles Outbreak Spreads; Using AI to Find PCPs
(MedPage Today) — Note that some links may require registration or subscription. Semaglutide (Wegovy) cut the risk for major heart events in people with obesity and cardiovascular disease regardless of how much weight they lost. (The Lancet… (MedPage Today) — Note that some links may require registration or subscription. Semaglutide (Wegovy) cut the risk Read More
Researchers seek to halt breast cancer recurrence by targeting “sleeper cells”Researchers seek to halt breast cancer recurrence by targeting “sleeper cells”
The results of a clinical trial published last month targeted breast cancer “sleeper cells,” which are cells that break away from the main tumor and can resurface later to spread cancer throughout the body.
Scientists seek to wipe out breast cancer’s “sleeper cells”Scientists seek to wipe out breast cancer’s “sleeper cells”
The results of a clinical trial published last month targeted breast cancer “sleeper cells,” which are cells that break away from the main tumor and can resurface later to spread cancer throughout the body. Elaine Quijano reports.
Wegovy has heart health benefits even if weight loss is minimalWegovy has heart health benefits even if weight loss is minimal
Studies have suggested that Wegovy directly boosts heart health, beyond just the benefits of losing weight, and now that has been demonstrated in a robust trial in people Studies have suggested that Wegovy directly boosts heart health, beyond just the benefits of losing weight, and now that has been demonstrated in a robust trial in Read More
Semaglutide helps heart regardless of how much weight lost, study revealsSemaglutide helps heart regardless of how much weight lost, study reveals
Anti-obesity medication semaglutide may help to prevent heart attacks and other major cardiac events regardless of how much weight people lose while taking the drug, according to a new study led by a UCL researcher. Anti-obesity medication semaglutide may help to prevent heart attacks and other major cardiac events regardless of how much weight people Read More
Study identifies factors affecting survival of patients with metastatic breast cancerStudy identifies factors affecting survival of patients with metastatic breast cancer
Researchers have identified factors associated with survival for patients initially diagnosed with metastatic breast cancer who were seen at UT Southwestern Medical Center and its affiliated sites. Their findings, published in Communications Medicine, list certain demographic and clinical characteristics to consider among the regional population when formulating treatment plans for individual patients.